Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bladder Cancer Sniffed Out by Urine Tester

By LabMedica International staff writers
Posted on 22 Jul 2013
A device has been developed that can help diagnose the early stages of bladder cancer by analyzing the gas emitted from urine.

The device analyzes the chemicals in the urine odor or headspace and produces a profile readout that shows whether cancer cells are present in the bladder.

Scientists at the University of Liverpool (UK) fabricated a new simple in-house gas chromatography (GC)-sensor device and evaluated it in the diagnosis of bladder cancer based on volatiles. More...
A total of 98 male patients, aged 27 to 91 years, were recruited from urology clinics. There were 24 with bladder cancer and 74 controls, who were patients undergoing investigation for symptoms of bladder outflow obstruction and or hematuria.

The presence of specific volatile organic compounds (VOCs) in the gas emitted from urine samples was analyzed using the in-house fabricated sensor system, called the Odoreader. This consisted of the Clarus 500 gas chromatography oven (PerkinElmer; Waltham, MA, USA) fitted with a commercially available capillary column (Sigma Aldrich; Dorset, UK) which was interfaced to a metal oxide sensor heated to 450 °C that was used as the detector. Additional assistance in evaluating the device was provided by investigators from the University of the West of England (Bristol, UK).

Analysis of the chromatograms showed that 83.3% of bladder cancer samples had a measurable peak in a specific region. In the control samples, peaks in that region of the spectra were predominantly absent. Sensor outputs were analyzed using two different, independent data analysis techniques each of which showed significant discrimination of samples from patients with and without bladder cancer. The identity of the VOCs that contribute to the biomarker profile has yet to be determined. Their characterization may be defined in future work using gas chromatography mass spectrometry techniques and this will provide further insight into bladder cancer induced biochemical changes.

Christopher S. Probert, MD, a senior author of the study said, “Bladder cancer is a disease that, if caught early, can be treated effectively, but unfortunately we do not have any early screening methods other than diagnosis through urine tests at the stage when it starts to become a problem. We have developed a device that can give us a profile of the odor in urine. It reads the gases that chemicals in the urine can give off when the sample is heated.” The study was published on July 8, 2013, in the journal Public Library of Science ONE.

Related Links:

University of Liverpool
PerkinElmer
Sigma Aldrich



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.